{
  "docId": "019de076-567f-77cd-b2fe-46fe5b90ebce",
  "docSlug": "f071473f2318bf29da28de95df17ba43",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 31,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a process flow diagram to map clinical outcomes to specific data points.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-567f-77cd-b2fe-46fe5b90ebce/11",
  "deckHref": "/decks/019de076-567f-77cd-b2fe-46fe5b90ebce",
  "deckJsonHref": "/decks/019de076-567f-77cd-b2fe-46fe5b90ebce.json",
  "deckAnchorHref": "/decks/019de076-567f-77cd-b2fe-46fe5b90ebce#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.88,
        "x": 0.06,
        "y": 0.3
      },
      "kind": "diagram",
      "text": "Five-step clinical outcome process flow",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2fe5353-24ce-47d6-8c58-d3720a30daa5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "list",
      "text": "EFA for MAT2203 was 0.42 (95% CI 0.29 to 0.55); 97% for patients receiving MAT2203; 76% for patients receiving SOC; Over 10 weeks, patients showed no breakthrough infections; 98% for patients receiving MAT2203; 88% for patients receiving IV AMPB; No renal toxicity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66f95ed5-04f0-45dc-85cf-52d09702ed68",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.15,
        "y": 0.18
      },
      "kind": "title",
      "text": "EnACT Clinical Data in Cryptococcal Meningitis Validates the Use of the LNC Platform to Enable Oral Administration and Overcome Toxicity",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "136235ea-46ef-4f9f-9d66-3e197d6f1fe0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "EnACT: Phase 2 Clinical Validation of Safety and Efficacy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b554f62-3391-4b7e-9e4d-321bb16b0a93",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "7a120a6f-c77a-445f-b481-79a8dc82f4ed",
      "evidence": "Sequential flow of clinical trial outcomes",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 16,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4e8350fd-f8e5-46e3-b847-1504c590f092",
      "evidence": "The Growing Threat of Invasive Fungal Infections (IFIs) and High Unmet Medical Need in Treatment of Invasive Aspergillosis (IA)",
      "position": 0,
      "objective": "Highlight the high unmet medical need in treatment of invasive aspergillosis (IA)",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}